SBIR TOPIC 415: Design and Construction of a Novel Electron Brachytherapy Source Driven by a Laser Plasma Accelerator

SBIR 主题 415：由激光等离子体加速器驱动的新型电子近距离治疗源的设计和构造

• 批准号: 10496713
• 负责人: STEVE GOURLAY
• 金额: $ 39.98万
• 依托单位: WOODTOGA HOLDINGS COMPANY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-16 至 2022-06-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10496713
• 关键词: Alpha Particles; Brachytherapy; Cancer Control; Data; Development; Devices; Dose; Dose-Rate; Electron Beam; Electrons; External Beam Radiation Therapy; Fast Neutrons; Fiber; Freedom; Gamma Rays; High-Dose Rate Brachytherapy; Isotopes; Lasers; Medical; Miniaturization; Optics; Physics; Physiologic pulse; Process; Radiation Oncology; Radiation therapy; Radioactive; Radioisotopes; Roentgen Rays; Small Business Innovation Research Grant; Source; Structure; System; Technology; Therapeutic; Time; Tissues; Translating; base; cancer site; cancer therapy; clinical practice; clinically relevant; design; design and construction; dosimetry; flexibility; improved; novel; operation; optical fiber; particle; plasma accelerator; programs; time use; tool; treatment optimization; treatment planning; two-photon

A. Background Information The long-term objective of this proposal is to advance the treatment of cancer using laser plasma accelerator physics breakthroughs at LBNL to build a miniature electron accelerator as a variable Xrays source with clinically relevant dose-rates of ~0.7 Gy/min and energies between 0.25 – 5 MeV. This electronic particle brachytherapy source is powered by a commercial, laser system, operating up to 1000 Hz and 7 W of average power. The flexibility of the laser driver allows treatment with radioisotope-free operation and variable x-ray energy on a pulse-by-pulse basis. This confers extra degrees of freedom for the treatment planning process thus providing the clinician the ability to improve the dose delivery. Unwanted dose to nearby healthy tissue and critical structures is reduced. This proposal brings a world-class team together: LBNL in laser plasma accelerators and optical fiber-based delivery systems, Woodtoga to translate the technology into clinically relevant products with expertise in bonding and the creation of miniature X-ray devices, and Varian Medical Systems as the commercial partner. Integrating the technology with clinical practice, treatment planning, into a radiation oncology platform transforming the field of brachytherapy.

A.背景资料 该提案的长期目标是推进使用激光等离子体治疗癌症 LBNL加速器物理突破，建立一个微型电子加速器作为可变X射线 临床相关剂量率约为0.7戈伊/min，能量在0.25 - 5 MeV之间的放射源。 这种电子粒子近距离放射治疗源由商业激光系统供电， 到1000 Hz和7 W的平均功率。激光驱动器的灵活性允许使用 无放射性同位素操作和基于逐脉冲的可变X射线能量。这赋予额外的 治疗计划过程的自由度，从而为临床医生提供以下能力： 改善剂量输送。减少了对附近健康组织和关键结构的不必要剂量。 该提案汇集了世界一流的团队：LBNL在激光等离子体加速器和光学 基于纤维的输送系统，Woodtoga将该技术转化为临床相关产品 拥有粘合和微型X射线设备制造方面的专业知识， 商业伙伴。将该技术与临床实践、治疗计划相结合， 放射肿瘤学平台改变了近距离放射治疗领域。